All In Biotech

Drug Trial Radar · NCT04379869

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

A Combined Single Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of NNZ-2591 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jul 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

May 29, 2020

Primary completion

Feb 11, 2021

Study completion Feb 11, 2021

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
May 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of NNZ-2591 when administered to healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • NNZ-2591Drug

    Single dose of NNZ-2591

  • PlaceboDrug

    Comparator for double-blind MAD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability measured through Adverse Events /Serious Adverse EventsTime frame: 25 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Sydney, New South Wales, Australia

  • Linear Clinical Research, The Queen Elizabeth II Medical Centre

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.